Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A3CMGM5
Thu, 07.11.2024
APONTIS PHARMA AG
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted
Revenue growth for Single Pill combinations in 9M 2024 to EUR 26.2 million (9M 2023: EUR 17.9 million)
Novartis collaboration (asthma products) contributes EUR 5.6 million to revenues
EBITDA rises to EUR 2.7 million (9M 2023: EUR [ … ]
Wed, 30.10.2024
APONTIS PHARMA AG
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva’s public tender offer
Joint reasoned statement by Management Board and Supervisory Board published
Offer price of EUR 10.00 per share represents an attractive premium of around 52.9% compared to the closing price on 15 October 2024 and a premium of 38.3% com [ … ]
Wed, 16.10.2024
APONTIS PHARMA AG
APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary public purchase offer
APONTIS PHARMA and Zentiva signed an investment agreement today
Growth strategy of APONTIS PHARMA to be continued together with Zentiva
APONTIS PHARMA to benefit from the European footprint, the existing research and [ … ]
Fri, 09.08.2024
APONTIS PHARMA AG
APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 – forecast for the full year confirmed
Revenue growth for Single Pill combinations in the first half of 2024 to EUR 17.9 million (H1 2023: EUR 12.1 million), also due to a competitor’s temporary inability to deliver in first quarter of 2024
New [ … ]
Thu, 27.06.2024
APONTIS PHARMA AG
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company
Monheim / Rhein, 27 June 2024. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pill combinations in the German market, expands its Executive Board with a view t [ … ]
Thu, 27.06.2024
APONTIS PHARMA AG
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company
Monheim / Rhein, 27 June 2024. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pill combinations in the German market, expands its Executive Board with a view t [ … ]
Tue, 04.06.2024
APONTIS PHARMA AG
APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management
Mila Brückel appointed as Head of Supply Chain
Extensive expertise in managing global supply chain programs from positions at Merck Healthcare
Monheim / Rhein, 4 June 2024. APONTIS PHARMA AG (Ticker APPH [ … ]
Wed, 08.05.2024
APONTIS PHARMA AG
APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed
Growth in revenue of Single Pill combinations to EUR 8.8 million in Q1 2024 (3M 2023: EUR 6.6 million), also due to a competitor’s temporary inability to supply products
Cooperation busines [ … ]
Fri, 05.04.2024
APONTIS PHARMA AG
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast
Monheim / Rhein, 5 April 2024. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5) has entered into a five-year agreement with Novartis Pharma GmbH to take over the distribution and marketing of the patent-protected medi [ … ]
Thu, 28.03.2024
APONTIS PHARMA AG
APONTIS PHARMA expects profitable growth again in 2024
Total sales 2023 of EUR 37.0 million exceed reduced forecast of EUR 36.1 million (2022: EUR 55.7 million)
EBITDA 2023 at EUR -7.7 million before restructuring expenses (forecast: EUR -8.6 million before restructuring expenses)
One-off restructuring expenses of EUR 5.6 million at the lower [ … ]